FDA Expands Accelerated Approval of Sevabertinib for HER2-Mutant Non-small Cell Lung Cancer

The FDA has expanded the accelerated approval of Sevabertinib for treating patients with HER2-mutant non-small cell lung cancer, providing a new regulatory pathway for rapid patient access to this targeted therapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it.